SALT
LAKE CITY, Aug. 16, 2023 /PRNewswire/
-- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the
"Company" or "Co-Dx"), a molecular diagnostics company with a
unique, patented platform for the development of molecular
diagnostic tests, announced today that the Company will be hosting
a booth this week at Asia Health/Medlab Asia 2023 from August 16-18 at the IMPACT Exhibition Center in
Bangkok, Thailand.
The Asia Health/Medlab Asia conference is intended to bring
together healthcare and laboratory communities to network and do
business in what the conference website describes as the region's
most valuable platform for the healthcare industry, with over 7,500
visitors, delegates, distributors, and senior lab and healthcare
executives expected to be in attendance.
The Company's booth will showcase Co-Diagnostics'
state-of-the-art Co-Primer™ PCR technology and infectious disease
products to conference attendees, along with its upcoming Co-Dx PCR
Home testing platform which is subject to FDA review and is not
available for sale.
Additional details, including registration information, can be
found here.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR Home™ platform and to locate genetic
markers for use in applications other than infectious disease.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-medlab-asia-conference-in-bangkok-thailand-301902656.html
SOURCE Co-Diagnostics